Company news
Ultragenyx Pharmaceutical Inc. news in 2020
Ultragenyx Pharmaceutical Inc.'s news releases, calls and decks from 2020, newest first.
Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta
December 16, 2020
Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson Disease
December 8, 2020
Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare Diseases
November 8, 2020
Ultragenyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
November 1, 2020
Ultragenyx Announces Pricing of Public Offering of Common Stock
October 27, 2020
Ultragenyx Reports Third Quarter 2020 Financial Results and Corporate Update
October 26, 2020
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy
October 22, 2020
Ultragenyx Appoints Mardi C. Dier as Chief Financial Officer
September 1, 2020
Ultragenyx Expands Leadership Team and Appoints Ernie Meyer as Chief Human Resources Officer
August 31, 2020
Ultragenyx Reports Second Quarter 2020 Financial Results and Corporate Update
July 29, 2020
Ultragenyx Announces U.S. Commercial Launch of Dojolvi™ (triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders
July 21, 2020
Ultragenyx Announces U.S. FDA Approval of Dojolvi™ (UX007/triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders
June 29, 2020
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)
June 17, 2020
Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics
May 20, 2020
Ultragenyx Announces Positive Data from Confirmatory Cohort of Phase 1/2 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
May 14, 2020
Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
May 12, 2020
Ultragenyx Reports First Quarter 2020 Financial Results and Corporate Update
May 5, 2020
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2020 Virtual Annual Meeting
April 27, 2020
Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology
March 30, 2020
Ultragenyx Announces Planned Transition of Chief Financial Officer
March 2, 2020
Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)
February 26, 2020
Ultragenyx Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update
February 12, 2020
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2019 Financial Results and Corporate Update
February 5, 2020
Ultragenyx Reports Preliminary 2019 Revenue and Provides 2020 Crysvita Revenue Guidance
January 12, 2020
Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
January 8, 2020